28th Oct 2015 08:49
LONDON (Alliance News) - Oxford Biomedica PLC on Wednesday said pharmaceutical giant GlaxoSmithKline PLC has exercised its option to acquire a non-exclusive licence for two rare orphan disease indications under the LentiVector platform owned by Oxford Biomedica.
The deal follows an agreement the pair signed in December 2013. No financial details were disclosed.
"This news further underlines the growing importance and demand for Oxford BioMedica's leading technology and IP. We are pleased that GSK are using our unique lentiviral vector platform and hope they can rapidly advance the development of new treatments that will benefit patients suffering from rare orphan indications for whom current treatment options are limited," said Oxford Biomedica Chief Executive John Dawson.
Shares in the company were up 6.2% to 6.9164 pence on Wednesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford BiomedicaGlaxosmithkline